Skip to Main Content
New Look! CDAS Redesigned
Posted by CDAS Administrator on Nov. 16, 2015, 10:04 a.m.

CDAS has been redesigned to incorporate an improved user interface and several new features. Start a new project or click on My Projects in the upper right corner to see a list of the projects you already have access to. Contact Us if you have any questions navigating the new site.

Preliminary applications will only be accepted from approximately December 1, 2015, through January 18, 2016.If you plan to submit a grant application this cycle, an approved preliminary grant application is required. Please note that this has changed from previous application cycles. Once your preliminary grant application has been approved, you will receive a confirmation letter to accompany your grant application.

Information is available regarding the PLCO trial and biospecimens.

Due to administrative factors and uncertainty in website development, the timeline for the release of the preliminary application and upcoming review cycle will be subject to changes. Please check CDAS frequently for an updated timeline. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

PLCO EEMS Round 21 will begin accepting preliminary applications in December 2015
Posted by CDAS Administrator on Nov. 2, 2015, midnight in PLCO

Preliminary applications for PLCO EEMS Round 21 will only be accepted from approximately December 1, 2015, through January 3, 2016. If you plan to submit an EEMS application this cycle, an approved preliminary application is required. Please note that this has changed from previous application cycles. Once your preliminary application has been approved, you will be notified and you will be able to continue and submit a full application. The deadline for full application submission is March 1, 2016.

Information is available regarding the PLCO trial and biospecimens.

Due to administrative factors and uncertainty in website development, the timeline for the release of the preliminary application and upcoming review cycle will be subject to changes. Please check CDAS frequently for an updated timeline. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

New PLCO Data: SCU Ancillary data and Vitamin D lab results
Posted by CDAS Administrator on June 11, 2014, 1 a.m. in PLCO

New PLCO cancer data added. Data version: may14.d052114

  • New Inadequate FSG variables:
    • The variables fsgin0/3/5/35 were removed from the colon person file.
    • The new variable fsg_in was added to the screening file, and the variables fsg_in0/3/5/35 were added to the person file. See documentation for variable formats.
  • New Hematopoetic Cancer Type variable:
    • The variable hema_type was given a new format in the hema_prsn file. See documentation for variable formats.
    • The variable hema_subtype has been dropped.
  • New SCU Complications variable indicating whether or not a complication was added from the SCU data.
  • Hematopoietic Non-target Misc Cancers:
    • Cancers with ICD codes classified as Non-Hodgkins Lymphoma, myeloproliferative disease, or myelodysplastic syndrome have been improved by classifying them as confirmed borderline hematopoietic cancers.

New PLCO ancillary study data added:

New PLCO lab data added:

The total PLCO population now has 154,898 participants. Over the course of the trial this number decreases due to participants withdrawing, improper consent at randomization or duplication at randomization.

New NLST data: non-lung cancer and AJCC 7 lung cancer stage
Posted by CDAS Administrator on June 11, 2014, 1 a.m. in NLST

Data on non-lung cancer and AJCC 7 lung cancer stage have been added to the NLST datasets.

For all non-lung cancers diagnosed during NLST, the ICD-O-3 code and timing of diagnosis (days from randomization) are now available in the participant dataset.

For all lung cancers diagnosed during NLST, the overall AJCC 7 stage has been added to the participant dataset, and more detailed AJCC 7 information (pathologic and clinical TNM components) is in the lung cancer dataset.

All previously available data remain available and essentially unchanged. No datasets, variables, or records were deleted. A few existing variables had their values change.

  • In the progression dataset, the "site" variables were corrected so that every instance of lung cancer progression has data on the site of progression. Previously, some instances of progression had all site variables set to “No”, which was incorrect.
  • In the participant dataset, values were corrected (from “No” to “Missing”) for some baseline variables (work history, disease history). These changes should be inconsequential for most analyses. They affected fewer than 1000 participants, and no single variable changed for more than 202 participants.

New NLST lung cancer staging data added:

New NLST non-long cancer data added: